Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 233

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 233
---
 |   |
| Personnel expenses (including stock-based compensation) |     |                    |    364,639 |   |     |      |    295,342 |   |
| General and administrative                              |     |                    |  1,236,157 |   |     |      |  1,184,556 |   |
| Change in fair value of warrant liability               |     |                    |     (1,417 | ) |     |      |    (68,427 | ) |
| Other income (expense), net(2)                          |     |                    |    (42,485 | ) |     |      |    847,722 |   |
| Net loss                                                |     | $                  | (2,051,085 | ) |     | $    | (2,681,433 | ) |

| (1) | Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, and other unallocated costs.     |
| (2) | Clinical trial related settlement expenses with A-IR Clinical Research Ltd., foreign currency transaction gains and losses and interest income from our cash balances in savings accounts. |

F-41 REVELATION BIOSCIENCES, INC. Up to 1,639,344 Shares of Common Stock 1,639,344 Pre-Funded Warrants to Purchase up to 1,639,344 Shares of Common Stock and up to 1,639,344 Shares of Common Stock Underlying the Pre-Funded Warrants Up to 3,278,688 Class H-1 Common Stock Warrants to Purchase up to 3,278,688 Shares of Common Stock (which contains a zero exercise price option) and up to 3,278,688 Shares of Common Stock Underlying the Class H-1 Common Stock Warrants Up to 3,278,688 Class H-2 Common Stock Warrants to Purchase up to 3,278,688 Shares of Common Stock and up to 3,278,688 Shares of Common Stock Underlying the Class H-2 Common Stock Warrants Up to 1,639,344 Class H-3 Common Stock Warrants to Purchase up to 1,639,344 Shares of Common Stock and- 1,639,344 Shares of Common Stock Underlying the Class H-3 Common Stock Warrants PRELIMINARY PROSPECTUS Roth Capital Partners May , 2025 PART II. INFORMATION NOT REQUIRED IN PROSPECT